


# Behavidence Unveils Clinical Findings Revealing Ability to Predict Postpartum Depression

*Behavidence revealing the ability of its app to predict postpartum depression in women between 8 weeks and 6 months after giving birth.*

NEW YORK, NY, UNITED STATES, February 14, 2023 /EINPresswire.com/ -- [Behavidence](#), a leading digital phenotyping company focused on mental health, announces new clinical findings revealing the ability of its app to predict postpartum depression in women between 8 weeks and 6 months after giving birth.



Behavidence App

The results of the small case study evaluation of 11 women in Greece, showed that the

“

The ability to predict postpartum depression, as well as major depression, with high accuracy is a critical step forward in improving mental health outcomes for women and their families”

*Roy Cohen, CEO*

Behavidence app was able to identify individuals who suffered from postpartum depression using digital markers which track behavior through app usage on their mobile phones. The app uses AI-driven algorithms, trained on usage patterns of thousands of patients, aimed to analyze delicate changes in cell phone usage to provide a comprehensive assessment of mental health.

This new development adds value to recent advancements in the treatment of postpartum depression by companies such as [SageRx](#), Biogen, and Shionogi, who are also working on solutions to improve mental health outcomes

for women during and after pregnancy.

"Our findings demonstrate the potential of digital phenotyping to transform the way we approach mental health assessment and treatment," said Roy Cohen, CEO of Behavidence. "The

ability to predict postpartum depression, as well as major depression, with high accuracy is a critical step forward in improving mental health outcomes for women and their families."

Most importantly, digital biomarkers play a significant role in the growth of precision medicine and can reduce clinical error, , improving the accuracy of diagnostic methods, and so support personalized therapeutic decisions.



Behavidence Founders: Dr. Girish Srinivasan, Dr. Janine Ellenberger and Roy Cohen

Behavidence is committed to leveraging the latest in AI and digital technology to improve mental health outcomes. Moreover, Behavidence is completely passive and uses only de-identified information, posing no risk to the user's privacy. The team at Behavidence are dedicated to creating a world where mental health is measurable, valued, and accessible to all.

For more information, please contact [health@behavidence.com](mailto:health@behavidence.com).

Dr. Janine Ellenberger  
Behavidence

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/616960620>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.